Posted by Michael Wonder on 21 Oct 2023
FDA approves Penbraya, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
20 October 2023 - The FDA’s decision is based on data from Phase 2 and Phase 3 trials, which demonstrated that Penbraya has robust immunogenicity non-inferior to Trumenba + Menveo for all serogroups and was well-tolerated with a favourable safety profile.
Pfizer announced today that the US FDA has approved Penbraya (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
